Why do some breast cancer cells remain dormant?

References

• Stein M, Loberant N, Laviov M, Rennert G, Lachter J, Kutten A. Second cancer in patients treated for testicular seminoma. J Surg Oncol 1992; 49: 16–19
   PubMedGoogle Scholar
• Sanders M E, Schuyler P A, Dupont W D, Page D L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005; 103: 2481–2484
   PubMedGoogle Scholar
• Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427: 787
   PubMed Web of Science ®Google Scholar
• Nielsen M, Thomsen J L, Primdahl S, Dyreborg U, Andersen J A. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987; 56: 814–819
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364
   PubMed Web of Science ®Google Scholar
• Udagawa T, Fernandez A, Achilles E G, Folkman J, D'Amato R J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16: 1361–1370
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Bouman A, Heineman M J, Faas M M. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11: 411–423
   PubMed Web of Science ®Google Scholar
• Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999; 5: 3529–3533
   PubMed Web of Science ®Google Scholar
• Mor G, Sapi E, Abrahams V M, Rutherford T, Song J, Hao X Y, Muzaffar S, Kohen F. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 2003; 170: 114–122
   PubMed Web of Science ®Google Scholar
• Song R X, Mor G, Naftolin F, McPherson R A, Song J, Zhang Z, Yue W, Wang J, Santen R J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 2001; 93: 1714–1723
   PubMedGoogle Scholar
• Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F. Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000; 73: 185–194
   PubMed Web of Science ®Google Scholar
• Gutierrez L S, Eliza M, Niven-Fairchild T, Naftolin F, Mor G. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999; 54: 245–253
   PubMed Web of Science ®Google Scholar
• Diel I J, Kaufmann M, Costa S D, Holle R, von Minckwitz G, Solomayer E F, Kaul S, Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652–1658
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Raulet D. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002; 188: 9–21
   PubMed Web of Science ®Google Scholar
• Walker L S, Abbas A K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002; 2: 11–19
   PubMed Web of Science ®Google Scholar
• Huang A Y, Bruce A T, Pardoll D M, Levitsky H L. In vivo crosspriming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4: 349–355
   PubMed Web of Science ®Google Scholar
• Emens L A, Reilly R T, Jaffer E M. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 2005; 12: 1–17
   PubMed Web of Science ®Google Scholar
• Curran E M, Berghaus L J, Vernetti N J, Saporita A J, Lubahn D B, Estes D M. Natural killer cells express estrogen receptor-α and estrogen receptor-β and can respond to estrogen via a non-estrogen receptor-α mediated pathway. Cell Immunol 2001; 214: 12–20
   PubMed Web of Science ®Google Scholar
• Gustafsson J A. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998; 2: 508–511
   PubMedGoogle Scholar
• Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 1998; 54: 105–112
   PubMed Web of Science ®Google Scholar
• Sabbioni M E, Siegrist H P, Bacchi M, Bernhard J, Castiglione M, Thurlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, et al. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat 2000; 59: 279–287
   PubMedGoogle Scholar
• Fairey A S, Courneya K S, Field C J, Bell G J, Jones L W, Mackey J R. Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol 2005; 98: 1534–1540
   PubMed Web of Science ®Google Scholar
• Zorica D J, Konstantinovic Z N, Stanojkovic T P, Zizak Z, Srdic T, Milosevic D, Jovanovic D. The antitumor immune response in HER-2 positive, metastatic breast cancer patients. J Transl Med 2005; 3: 13
   PubMedGoogle Scholar
• von Mensdorff-Pouilly S, Verstraeten A A, Kenemans P, Snijdewint F GM, Kok A, Van Kamp G J, Paul M A, Van Diest P J, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18: 574–583
   PubMed Web of Science ®Google Scholar
• Rosner B, Colditz G, Willet W. Reproductive risk factors in a prospective study of breast cancer: The Nurse's Health Study. Am J Epidemiol 1994; 139: 819–835
   PubMed Web of Science ®Google Scholar
• Yoo K Y, Tajima K, Kuroishi T, Hirose K, Yoshida M, Miura S, Murai H. Independent protective effect of lactation against breast cancer: a case–control study in Japan. Am J Epidemiol 1992; 135: 726–733
   PubMed Web of Science ®Google Scholar
• Russo J, Russo I H. Differentiation and breast cancer. Medicina (B Aires) 1997; 57(Suppl 2)81–91
   PubMedGoogle Scholar
• Nicolini A, Carpi A, Rossi G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J Immunother 2005; 28: 276–279
   PubMedGoogle Scholar
• Polanczyk M J, Carson B D, Subramanian S, Afentoulis M, Vandenbark A A, Ziegler S F, Offner H. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004; 173: 2227–2230
   PubMed Web of Science ®Google Scholar
• Cheng F, Gabrilovich D, Sotomayor E M. Immune tolerance in breast cancer. Breast Dis 2004; 20: 93–103
   PubMedGoogle Scholar
• Stein M, Schiavi R C, Camerino M. Influence of brain and behavior on the immune system. Science 1976; 191: 435–440
   PubMed Web of Science ®Google Scholar
• London O D. Aspirin could be used to prevent cancer. Br Med J 2003; 326: 565
   PubMedGoogle Scholar
• Harris R, Chlebowski R T, Jackson R D, Frid D J, Ascenseo J L, Anderson G, Loar A, Rodabough R J, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs. Cancer Res 2003; 63: 6096–6101
   PubMed Web of Science ®Google Scholar
• Muck A O, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 2004; 42: 695–700
   PubMed Web of Science ®Google Scholar
• Stamm J A, Ornstein D L. The role of statins in cancer prevention and treatment. Oncology (Williston Park) 2005; 19: 739–750, discussion 753–754
   PubMedGoogle Scholar
• Shun M C, Yu W, Gapor A, Parsons R, Atkinson J, Sanders B G, Kline K. Pro-apoptotic mechanisms of action of a novel vitamin E analog (α-TEA) and a naturally occurring form of vitamin E (δ-tocotrienol) in MDA-MB-435 human breast cancer cells were reported. Nutr Cancer 2004; 48: 95–105
   PubMed Web of Science ®Google Scholar
• Sylvester P W, Shah S J. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci 2005; 10: 699–709
   PubMed Web of Science ®Google Scholar
• Wang X F, Witting P K, Salvatore B A, Neuzil J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun 2005; 326: 282–289
   PubMed Web of Science ®Google Scholar
• Zhang S M. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol 2004; 16: 19–25
   PubMed Web of Science ®Google Scholar
• Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther 2004; 3: 333–341
   PubMedGoogle Scholar
• Knoops K, Groot L, Kromhout D, Perrin A E, Moreiras-Varela O, Menotti A, van Staveren W A. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women. J Am Med Assoc 2004; 292: 1433–1439
   PubMed Web of Science ®Google Scholar
• Wu A, Arakawa K, Stanczyk F, Van Den Berg D, Koh W P, Yu M C. Tea and circulating estrogen levels in postmenopausal Chinese women in Singapore. Carcinogenesis 2005; 26: 976–980
   PubMed Web of Science ®Google Scholar
• Kodama M, Kodama T, Miura S, Yoshida M. Nutrition and breast cancer risk in Japan. Anticancer Res 1991; 11: 745–754
   PubMedGoogle Scholar
• Kruk J, Aboul-Eneim H Y. Psychological stress and the risk of breast cancer: a case–control study. Cancer Detect Prev 2004; 28: 399–408
   PubMedGoogle Scholar
• Montazeri A, Jarvandi S, Ebrahimi M, Haghighat S, Ansari M. The role of depression in the development of breast cancer: analysis of registry data from a single institute. Asian Pac J Cancer Prev 2004; 5: 316–319
   PubMedGoogle Scholar
• Triebel F, Hacene K, Pichon M F. A soluble lymphocyte activation gene-3 sLAG-3 protein is a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett Jun 7, 2005, [Epub ahead of print]
   PubMedGoogle Scholar
• Fentiman I S. Timing of surgery for breast cancer. Int J Clin Pract 2002; 56: 188–190
   PubMedGoogle Scholar
• Cooper L S, Gillett C E, Smith P, Fentiman I S, Barnes D M. Cell proliferation measured by MIB1 and timing of surgery for breast cancer. Br J Cancer 1998; 77: 1502–1507
   PubMedGoogle Scholar
• Saad Z, Bramwell V H, Wilson S M, O'Malley F P, Jeacock J, Chambers A F. Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 1998; 351: 1170–1173
   PubMedGoogle Scholar